The current CFO, John Gandolfo, will remain with the company until November as part of a planned retirement transition.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN ), a commercial-stage ophthalmology company with two FDA-approved products and an asset in late-stage pediatric progressive myopia, today announced the appointment of Andrew Jones as CEO Finance and accounting with experience as a senior financial manager. Mr. Jones brings to the Eyenovia team more than 30 years of diverse financial management and accounting experience in the therapeutics and medical technology/devices space, most recently as Chief Financial Officer of NovaBay Pharmaceuticals, Inc. It has been a commercial ophthalmology company in the stage of public trading. Eyenovia’s current CFO, John Gandolfo, is retiring and will remain with the company until November to help ensure a smooth transition.
“We are delighted to welcome Andrew to the Eyenovia team and believe his diverse and relevant experience is a perfect fit for our company at this important juncture,” said Eyenovia CEO Michael Rowe. As we approach critical data reviews for MicroPine later this year, the US launch of clobestazole, as well as the continued commercial ramp-up of Mydcombi, we will be building on Andrew’s track record of success – both in operations as well as capital raising. Ensure that we are best positioned for long-term success.”
Additionally, on behalf of the entire Eyenovia team, I would like to thank John Gandolfo for his many contributions since joining the company in 2017. We have made tremendous progress during this time and I wish him well in his retirement.
Eyenovia’s commercial strategy is progressing rapidly, with two FDA-approved products and a third in late Phase 3 development, in addition to several collaboration agreements that have the potential to further advance and expand the use of Optejet technology already proven to address Other great things. Offer ophthalmic indications in the market. Mr. Andrew Jones stated. “With many opportunities for long-term growth and value creation, I am excited to join the Eyenovia team as it works to develop highly differentiated topical ophthalmic medicines.”
Prior to joining Eyenovia, Mr. Jones served as CFO and Treasurer of NovaBay Pharmaceuticals during a successful period of business growth and cost reduction. Prior to joining NovaBay, he served as Vice President of Finance at MyoScience, Inc., a company that successfully developed and commercialized a pain management device through its acquisition by Pacira BioSciences. Life sciences companies including Armetheon, Inc., Asante Solutions, Inc. and Genelabs Technologies, Inc., and began working with PricewaterhouseCoopers. Mr. Jones received a bachelor’s degree in business administration from the University of Washington in Seattle.
Nasdaq Rule 5635(c)(4) Notice
In connection with his commencement, Mr. Jones was granted an option to purchase 200,000 shares of the Company’s common stock at a price equal to the closing price per share of the Company’s common stock on the date. August 30, 2024. Such option is subject to a four-year schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments upon Mr. Jones thereafter, three years of continuous service to the Company. The compensation committee of Eyenovia’s board of directors approved the award as an incentive to hire Mr. Jones in accordance with Nasdaq Listing Rule 5635(c)(4).
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN ) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array imprinted therapies. Eyenovia is currently focused on commercializing MYDCOMBI® for mydriasis, clobetasol propionate ophthalmic suspension, 0.05% for postoperative pain and inflammation, as well as ongoing late-stage development of drugs in the Optejet device for pediatric progressive myopia, as well as licensing for additional indications. Visit Eyenovia.com for more information.
Eyenovia’s corporate information slide deck can be found at ir.eyenovia.com/events-and-presentations.
Please to MYDCOMBI.COM For important safety information for MYDCOMBI™ (tropamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%
Please to CLOBETASOLBID.COM For important safety information for clobetasol proprionate ophthalmic suspension 0.05%
Forward-looking statements
Except for historical information, all statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, forecasts or any other statements regarding our future operations or other future events or conditions, including opportunities the estimated market for our product candidates and platform technology, and the timing for availability and sales growth of our approved products; These statements are based on current expectations, estimates and projections about our business, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results and outcomes may, and in some cases likely, differ from those expressed or projected in forward-looking statements due to various factors that may be discussed from time to time in documents we file on U.S. securities exchanges. It is argued that there is a fundamental difference. Commission.
In addition, such statements could be affected by risks and uncertainties associated with: the risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; our timing and ability to submit applications to obtain and maintain regulatory approvals for our products and product candidates; the potential benefits of our products, product candidates and platform technology; the rate and degree of market acceptance and clinical application of our products and product candidates; our estimates of the potential market opportunity for our products and product candidates; reliance on third parties to develop and commercialize our products and product candidates; our and our partners’ ability to develop, implement and maintain timely manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; intellectual property risks; changes in the legal, regulatory, legal and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; and our competitive position
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia undertakes no obligation to update any forward-looking statements.
Contact Eyenovia:
Eyenovia, Inc.
Andy Jones
Chief Financial Officer
ajones@eyenovia.com
Eyenovia investor contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Contact Eyenovia Media:
Eyenovia, Inc.
Norbert Lowe
Vice President of Business Operations
nlowe@eyenovia.com